Roth Capital analyst Scott Henry reiterated a Buy rating on Tonix Pharmaceuticals (NASDAQ:TNXP) with a $10 price target, following the company’s third-quarter results. reporting a 3Q14 EPS …
Roth Capital analyst Scott Henry reiterated a Buy rating on Tonix Pharmaceuticals (NASDAQ:TNXP) with a price target of $10.00, which represents a potential upside …
In a research note issued August 11, Roth Capital analyst Scott Henry maintained coverage with a Buy rating on Tonix Pharmaceuticals (TNXP) and a $17 price target, following the …
